User contributions for Lazy

28 April 2024

• 10:4310:43, 28 April 2024 diff hist +2,257‎ Main Page ‎ →‎Cancer Stem Cells (CSCs) in Glioblastoma: Challenges with Standard of Care (SOC)
• 10:3710:37, 28 April 2024 diff hist +32‎ Main Page ‎ →‎Conclusion
• 10:3510:35, 28 April 2024 diff hist +79‎ Main Page ‎ →‎Conclusion
• 10:3310:33, 28 April 2024 diff hist +2,662‎ Main Page ‎ →‎The Standard of Care for Initial Treatment
• 10:2710:27, 28 April 2024 diff hist −3‎ MGMT ‎ →‎The role of MGMT current

12 April 2024

• 13:5513:55, 12 April 2024 diff hist +1,264‎ Curcumin ‎No edit summary current
• 13:3213:32, 12 April 2024 diff hist +118‎ Template:TreatmentInfo ‎No edit summary current
• 13:3113:31, 12 April 2024 diff hist +1‎ Melatonin ‎No edit summary current
• 13:3013:30, 12 April 2024 diff hist +621‎ Melatonin ‎No edit summary
• 13:2313:23, 12 April 2024 diff hist +2,113‎ Melatonin ‎No edit summary

5 April 2024

• 21:1921:19, 5 April 2024 diff hist +4,314‎ Vitamin D ‎No edit summary current
• 21:1921:19, 5 April 2024 diff hist +5,039‎ Melatonin ‎No edit summary
• 21:1921:19, 5 April 2024 diff hist +3,962‎ Thyroid Hormone T4 (Thyroxine) Suppression ‎No edit summary current
• 21:1921:19, 5 April 2024 diff hist +5,763‎ N Beta-blockers (especially propranolol) and the role of the sympathetic ‎ Created page with " {{TreatmentInfo |drug_name=Beta-blockers (especially propranolol) and the role of the sympathetic |category=Hormones and Cancer Therapy |book_text=nervous system Recenty the role of the sympathetic nervous system in cancer progression, and the potential role of beta-adrenergic antagonists (beta-blockers) have come into focus in some corners of the cancer research community. Early studies linking stress to increased rates of cancer progression led to epidemiological st..." current
• 21:1921:19, 5 April 2024 diff hist +3,370‎ N Angiotensin-Il Receptor Blockers (ARB) ‎ Created page with " {{TreatmentInfo |drug_name=Angiotensin-Il Receptor Blockers (ARB) |category=Hormones and Cancer Therapy |book_text=Angiotensin-II is a peptide hormone produced from angiotensin-I by the action of angiotensin converting enzyme (ACE). The main effect of angiotensin-II is vasoconstriction and a resulting increase in blood pressure. Therefore ACE inhibitors and angiotensin-II receptor blockers are used as anti-hypertensive drugs, especially in heart disease. More recently..." current
• 21:1821:18, 5 April 2024 diff hist +1,525‎ N Herpes Virus ‎ Created page with " {{TreatmentInfo |drug_name=Herpes Virus |category=Oncolytic virotherapy |book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials used a retrovirus version, which infects only those cells dividing when the virus was infused. Subsequent trials have used an adenovirus version, which infects both dividing and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to proliferate, soon after the virus..." current
• 21:1821:18, 5 April 2024 diff hist +581‎ N Newcastle Disease Virus ‎ Created page with " {{TreatmentInfo |drug_name=Newcastle Disease Virus |category=Oncolytic virotherapy |book_text=An alternative approach to vaccine treatment utilizes viruses. Newcastle disease is a lethal chicken disease, which is caused by a virus that is innocuous to humans, causing only transitory mild flu-like symptoms. It was developed as a cancer treatment in Hungary but has largely been ignored in this country until only recently. Newcastle Disease Virus is currently being utiliz..." current
• 21:1821:18, 5 April 2024 diff hist +824‎ N DNX-2401 adenovirus ‎ Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event..." current
• 21:1821:18, 5 April 2024 diff hist +916‎ N Genetically modified Poliovirus (PVS-RIPO) ‎ Created page with " {{TreatmentInfo |drug_name=Genetically modified Poliovirus (PVS-RIPO) |category=Oncolytic virotherapy |book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost in public interest when an episode of the television show 60 minutes was devoted to it. Most exceptionally, the first two patients treated in this study were complete responders. As of March 2015 (when the 60 minutes special aired) these two complete responders were st..." current

31 March 2024

• 15:4015:40, 31 March 2024 diff hist −21‎ Template:PropertyTableFormat ‎No edit summary current
• 15:3915:39, 31 March 2024 diff hist −162‎ Main Page ‎ →‎Other Chemotherapy and Cancer Drugs
• 15:3815:38, 31 March 2024 diff hist −112‎ Main Page ‎ →‎Antibody-Drug Conjugates and other protein-drug conjugates
• 15:3815:38, 31 March 2024 diff hist −414‎ Main Page ‎ →‎Tumor-associated antigen vaccines
• 15:3715:37, 31 March 2024 diff hist −107‎ Main Page ‎ →‎Tumor-associated antigen vaccines
• 15:3515:35, 31 March 2024 diff hist −2‎ Template:PropertyTableFormat ‎No edit summary Tag: Manual revert
• 15:3415:34, 31 March 2024 diff hist −10‎ Template:PropertyTableFormat ‎No edit summary Tag: Reverted
• 15:3315:33, 31 March 2024 diff hist +2‎ Template:PropertyTableFormat ‎No edit summary Tag: Reverted
• 15:3115:31, 31 March 2024 diff hist +10‎ Template:PropertyTableFormat ‎No edit summary Tag: Reverted
• 15:3015:30, 31 March 2024 diff hist +172‎ Main Page ‎No edit summary
• 15:2715:27, 31 March 2024 diff hist +84‎ Template:PropertyTableFormat ‎No edit summary
• 15:2315:23, 31 March 2024 diff hist +456‎ Main Page ‎No edit summary
• 15:1615:16, 31 March 2024 diff hist +44‎ ICT-107 ‎No edit summary current
• 14:3214:32, 31 March 2024 diff hist +45‎ SL-701 ‎No edit summary current
• 14:3114:31, 31 March 2024 diff hist +45‎ Anti-CMV Dendritic Cell Vaccine ‎No edit summary current
• 14:3114:31, 31 March 2024 diff hist +44‎ Rindopepimut (CDX-110) ‎No edit summary current
• 14:3014:30, 31 March 2024 diff hist +44‎ Wilms Tumor 1 (WT1) Peptide Vaccine ‎No edit summary
• 14:2714:27, 31 March 2024 diff hist +2,921‎ N Wilms Tumor 1 (WT1) Peptide Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi..."
• 14:2314:23, 31 March 2024 diff hist +3,809‎ N Rindopepimut (CDX-110) ‎ Created page with "{{TreatmentInfo |drug_name=Rindopepimut (CDX-110) |FDA_approval=Not FDA-approved; received Breakthrough Therapy designation for glioblastoma in Feb 2015 |used_for=EGFRvIII-positive Glioblastoma Multiforme (GBM) in newly diagnosed and recurrent cases |clinical_trial_phase=Phase III for newly diagnosed GBM was discontinued; Phase II for recurrent GBM showed promising results |common_side_effects=Transient, low-grade local reactions; overall well-tolerated |OS_without=Media..."
• 14:1914:19, 31 March 2024 diff hist +4,449‎ N Anti-CMV Dendritic Cell Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Anti-CMV Dendritic Cell Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Not detailed; dendritic cell vaccines are generally well-tolerated with mild side effects. |OS_without=Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM. |OS_with=Varied; one study showed medi..."
• 14:1414:14, 31 March 2024 diff hist +2,361‎ N SL-701 ‎ Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv..."
• 14:1014:10, 31 March 2024 diff hist +7,097‎ N ICT-107 ‎ Created page with "{{TreatmentInfo |drug_name=ICT-107 (Tumor-associated Antigen Vaccine) |FDA_approval=Still in clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase III |common_side_effects=Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported. |OS_without=Median overall survival for GBM typically rang..."
• 14:0614:06, 31 March 2024 diff hist +3,218‎ N Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Recurrent heavily pretreated glioblastoma multiforme (GBM) and newly diagnosed GBM |clinical_trial_phase=Phase II |common_side_effects=Not explicitly detailed; similar immunotherapy treatments often include flu-like symptoms, injection site reactions, fatigue |OS_without=Historical controls suggest a median survival t..." current
• 14:0114:01, 31 March 2024 diff hist +6,839‎ N Dendritic Cell Vaccine (DCVax-L) ‎ Created page with "{{TreatmentInfo |drug_name=Dendritic Cell Vaccine (DCVax-L) |FDA_approval=Under investigation; not yet FDA-approved |used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent |clinical_trial_phase=Phase 3 |common_side_effects=Intracranial edema, nausea, lymph node infection (rare and manageable) |OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence |OS_with=Median overall survival of 19.3 months..." current
• 13:5813:58, 31 March 2024 diff hist −14‎ BCNU (Carmustine) and Gliadel (Carmustine Wafers) ‎No edit summary current
• 13:5513:55, 31 March 2024 diff hist +2,150‎ Main Page ‎No edit summary
• 12:2612:26, 31 March 2024 diff hist −30‎ Template:TreatmentInfo ‎No edit summary
• 12:2512:25, 31 March 2024 diff hist +25‎ Template:TreatmentInfo ‎No edit summary
• 12:2412:24, 31 March 2024 diff hist −12‎ Template:TreatmentInfo ‎No edit summary
• 12:2312:23, 31 March 2024 diff hist +52‎ Template:TreatmentInfo ‎No edit summary
• 11:0311:03, 31 March 2024 diff hist +18‎ N Property:Has Toxicity Explanation ‎ Created page with "Has type::Text" current